

Maklumat tambahan indikasi untuk upload pada laman web

Year 2015

Products Approved For Additional Indication (DCA 295 – 7 Januari 2016)

NO	PRODUCT (ACTIVE INGREDIENT)	ADDITIONAL INDICATION	MARKETING AUTHORIZATION HOLDER
1.	1.1 Humira Solution For Injection [Adalimumab 40mg/0.8ml]	<p>➤ Indication:</p> <p><i><u>Hidradenitis Suppurativa</u></i> <i>Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.</i></p> <p>➤ Posology:</p> <p><i><u>Hidradenitis Suppurativa</u></i> <i>The recommended Humira dose regimen for adult patients with hidradenitis suppurativa (HS) is 160 mg initially at Day 1 (given as four 40mg injections in one day or as two 40mg injections per day for two consecutive days), followed by 80mg two weeks later at Day 15 (given as two 40 mg injections in one day). Two weeks later (Day 29) continue with a dose of 40 mg every week. Antibiotics may be continued during treatment with Humira if necessary.</i></p> <p><i>Should treatment need to be interrupted, Humira may be re-introduced.</i></p> <p><i>In patients without any benefit after 12 weeks of treatment, prescriber should consider to discontinue the treatment.</i></p>	<p><b>ABBVIE SDN BHD</b> No. 24, Jalan Pemaju U1/15, Seksyen U1, Hicom-Glenmarie Industrial Park, 40150 Shah Alam, Selangor.</p>